The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide comments in response to the Office of the United States Trade Representative’s (USTR) request for comments on the topic of “Advancing Inclusive, Worker-Centered Trade Policy.” PhRMA represents the country’s leading innovative biopharmaceutical research and manufacturing companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Over the last decade, PhRMA member companies have more than doubled their annual investment in the search for new treatments and cures, including nearly $101 billion in 2022 alone.